Growing Prevalence of Cancer
The growing prevalence of cancer patients has a direct impact on the increased demand for the exosomes market. According to the 2012 report of the World Health Organization (WHO), there were 14 million new cases of cancer, which were expected to rise by about 70% over the next two decades. In the US, as per the National Cancer Institute report of 2018, an estimated 1.7 million of new cases of cancer I diagnosed in the country and nearly 0.6 million patients died from the diseases. Exosomes extracted from cow milk is being used for the delivery of therapeutic molecules against lung and breast cancer. Moreover, exosomes derived from specific sites of the body are promising candidates for the anti-cancer vaccines due to its enhanced passive targeting due to small size, indigenous nature, and the ability to cross the biological barriers. Thus, the increase in the cancer cases in the hospitals directly increases the demand for the need of exosomes in its diagnosis as well therapeutics.
Other driving factors include technological advancements in exosomes isolation and analytical procedures, growth in the government initiatives, and funding for exosome research with increased advanced applications for exosomes.
Technical Difficulties with the Implementation and Usage of Exosomes
The number of technical difficulties needs to be addressed for successful implementation of exosomes in various applications. This is one of the primary hinderances for the growth of the exosomes market. Some of the major difficulties include optimization of purification, increasing the homogeneity of exosomes, and efficient transfection strategies. This is further accompanied by lack of technical information like type rotor, diameter, volume, and viscosity of the sample, which restricts the maximum utilization of exosomes potential. Moreover, the cumbersome nature of methods for isolation/purification and inability to distinguish between different cancer stages with incomplete understanding on the immune system limits the market.
Other factors limiting the growth of this market are the lack of skilled professionals and stringent regulatory requirements for the approval and commercialization of exosomes products.
North America to Dominate the Market
North America is the region with a high degree of market lucrativeness. It is primarily due to the technological advancements, increased geriatric population coupled with an increase in the incidences of chronic diseases, such as cancer and cardiovascular diseases, with increased acceptance of exosome-based products. On the other side, the Asia-Pacific countries are expected to show wide opportunities for growth in development of exosomes related therapeutics and diagnostics with emerging economies, healthcare improvement in facilities particularly due to the involvement of private companies and collaboration with multinational players.
Key Developments in the Market
- January 2018 - ArunA Biomedical launched a new class of cell-free exosomes biologics to treat central nervous system and neurodegenerative disorders.
- September 2017 - PureTech Health PLC exclusively licensed novel milk-derived exosome technology, Calix, from 3P Biotechnologies, Inc.
Reasons to Purchase the Report
- Current and future of the global exosomes market outlook in the developed and emerging markets.
- Analysis of various perspectives of the market with the help of Porter’s Five Forces Analysis.
- The segment that is expected to dominate the market.
- Regions that are expected to witness the fastest growth during the forecast period.
- Identify the latest developments, market shares, and strategies employed by the major market players.
- 3-month analyst support, along with the Market Estimate sheet (in Excel).
This report can be customized to meet your requirements. Please connect with our Customer Service team, who will ensure you to get a report that suits your needs.
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porter's Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitute Products and Services
5.2.5 Competitive Rivalry
6. Market Dynamics
6.1.1 Increasing Prevalence of Cancer
6.1.2 Technological Advancements in Exosomes Isolation and Analytical Procedures
6.1.3 Growth in Government Initiatives and Funding for Exosome Research
6.1.4 Increasing Advanced Applications of Exosomes
6.2.1 Stringent Regulatory Requirement for Approval and Commercialization of Exosomes Products
6.2.2 Technical Difficulties with the Implementation and Usage of Exosomes
6.2.3 Lack of Skilled Professionals
6.4 Key Challenges
7. Market Segmentation
7.1 By Isolation Method
7.1.2 Immunocapture on Beads
7.2 By Downstream Analysis
7.2.1 Cell Surface Marker Analysis through Flow Cytometry
7.2.2 Protein Analysis by Blotting & ELISA
7.2.3 RNA Analysis by NGS & PCR
7.3 By Application
7.3.1 Drug Delivery
7.3.2 Tumor Immunotherapy
7.3.3 Diagnostic Biomarkers
7.4 By Geography
7.4.1 North America
126.96.36.199 United States
188.8.131.52 United Kingdom
184.108.40.206 Rest of Europe
220.127.116.11 South Korea
18.104.22.168 Rest of Asia-Pacific
7.4.4 Middle East & Africa
22.214.171.124 South Africa
126.96.36.199 Rest of Middle East & Africa
7.4.5 South America
188.8.131.52 Rest of South America
8. Competitive Landscape
8.1 Mergers & Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Products Launches
9. Key Players
9.2 Diagenode, Inc.
9.3 Fujifilm Holdings Corporation
9.4 Hitachi Chemical Diagnostics, Inc.
9.6 MBL International
9.7 Miltenyi Biotec
9.8 Novus Biologicals
9.10 Thermo Fisher Scientific, Inc.
9.11 *List not Exhaustive
10. Future of the Market
- Danaher (Beckman Coulter Inc.)
- Diagenode Inc.
- Fujifilm Holdings Corporation
- Hitachi Chemical Diagnostics Inc.
- Mbl International
- Miltenyi Biotec
- Novus Biologicals
- Thermo Fisher Scientific Inc.